早期非大血管闭塞脑梗死药物治疗方案中分别应用替罗非班动、静脉不同给药方式的效果观察  

Observation on the Effect of Different Administration Methods of Tirofiban in the Treatment of Early-stage Non-large Vessel Occlusion Cerebral Infarction

作　　者：周翔 庞红立[1] 严澎[1] 李文波[1] ZHOU Xiang;PANG Hongli;YAN Peng;LI Wenbo(Department of Neurointervention,Luoyang Central Hospital,Luoyang 471000,Henan,China)

机构地区：[1]洛阳市中心医院神经介入科,河南洛阳471000

出　　处：《中国药物滥用防治杂志》2024年第9期1639-1642,共4页Chinese Journal of Drug Abuse Prevention and Treatment

基　　金：河南省医学科技攻关计划(联合共建项目)(编号:LHGJ20220945)。

摘　　要：目的:比较动静脉联合应用与单纯静脉应用替罗非班在治疗早期非大血管闭塞性脑梗死的安全性和临床疗效。方法:纳入2018年12月—2023年12月在洛阳市中心医院神经介入科治疗的非大血管闭塞脑梗死患者63例。根据是否行脑血管造影分为研究组(32例)和对照组(31例),研究组予以动静脉联合应用替罗非班,对照组单纯静脉应用替罗非班,比较两组安全性、NIHSS评分及治疗后90天mRS评分。结果:两组其他部位出血率及神经功能恶化率比较,差异均无统计学意义(P>0.05),且两组干预后48 h内症状性颅内出血发生率及90天死亡率均为零。研究组干预后24 h及7天NIHSS评分均低于对照组(P<0.05);90天后,研究组mRS评分≤2分患者比例高于对照组(P<0.05)。结论:对于早期非大血管闭塞性脑梗死患者,动静脉联合应用替罗非班相对于单纯应用替罗非班更加有效,改善NIHSS及MRS评分,提高日常生活能力。Objective:To compare the safety and clinical efficacy of combined arteriovenous and intravenous tirofiban in the treatment of early non-vascular occlusive cerebral infarction.Methods:From December 2018 to December 2023,63 patients with non-large vessel occlusion cerebral infarction treated in the Department of Neurointervention of Luoyang Central Hospital were included.According to whether cerebral angiography was performed,they were divided into study group(32 patients)and control group(31 patients).The study group was treated with arteriovenous combined with tirofiban,while the control group was treated with tirofiban alone.The safety,NIHSS score and mRS score at 90 days after treatment were compared between the two groups.Results:There was no significant difference in the rate of bleeding in other parts and the rate of neurological deterioration between the two groups(P>0.05),and the incidence of symptomatic intracranial hemorrhage within 48 hours after intervention and the 90-day mortality rate were zero in both groups.The NIHSS scores of the study group at 24 h and 7 days after intervention were lower than those of the control group(P<0.05).After 90 days,the proportion of patients with mRS score≤2 in the study group was higher than that in the control group(P<0.05).Conclusion:For patients with early-stage non-vascular occlusive cerebral infarction,arteriovenous combined with tirofiban is more effective than tirofiban alone,which can improve NIHSS and MRS scores,and improve the daily living ability.

关 键 词：替罗非班 动静脉联合 单纯静脉应用 早期非大血管闭塞性脑梗死 

分 类 号：R743.33[医药卫生—神经病学与精神病学]